171 results
Page 2 of 9
8-K
EX-10.4
aoq23yh8yu9w4ka95 4e
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
424B3
e37cl3i19 oozbi
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
EX-23.1
kibqmh5r1ac4t42augb6
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
S-4/A
cd0fdv48 d04vkle3s9
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
S-4/A
EX-23.2
dlkaukq mtrl9urkn
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
S-4
EX-23.1
o5kwb
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm
S-4
ab2x sm49s
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm
S-4
EX-23.2
kk4xtvqb6phbeq
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm
8-K
EX-99.1
tot2inqm
8 Nov 22
Adaptimmune Reports Third-Quarter Financial Results and Business Update
7:42am
8-K
EX-99.1
vb4a1c1p
9 Sep 22
Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors
7:14am
8-K
EX-10.1
pdotdmw flszsfuzw4be
4 May 22
Adaptimmune Announces Appointment of Joanna Brewer as Chief Scientific Officer
8:20am
424B5
n84gojzo2qx4h5mcniu
28 Apr 22
Prospectus supplement for primary offering
8:09am